Theravance Biopharma, Inc. Announces Top-line Results from a Pha
TBPH: Theravance Biopharma, Inc.
2021-09-15 06:05:00
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
2021-09-15 06:05:00
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension